N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,771 Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
Asthma
Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510
Phase 3 N=689 Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
Asthma
Primary: Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study — 202; 406; 26; 55 Participants
N/A N=233 Asthma Symptom Management Through Mindfulness Training
Asthma
Primary: Change From Baseline in Asthma Control at 18 Months — 1.27; 1.17 score on a scale
Phase 2 N=134 Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)
Asthma
Primary: Change From Baseline in FEV1 (Forced Expiratory Volume; Volume of Air That is Exhaled During the First Second of a Forced Exhalation) — 0.22; 0.17 L (Liter) — p=0.033
Phase 3 N=210 Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)
Asthma
Primary: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) — 24.4; 18.0; -1.4 Liters per minute
Phase 3 N=1,162 Montelukast Back to School Asthma Study (0476-340)
Asthma
Primary: Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants — 27.23; 24.26 Percentage of Days
Phase 2 N=68 Symptom Clusters in Children With Exacerbation-prone Asthma
Asthma in Children
Primary: Change in Asthma Control Questionnaire (ACQ) Score — 0.52 score on a scale
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
Phase 2 N=248 Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
Asthma
Primary: Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15 — 0.284; 0.261; 0.252; 0.237 Liter
Phase 3 N=295 Steroids In Eosinophil Negative Asthma
Asthma
Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…
Phase 2 N=21 Personalized Treatment Algorithms for Difficult-to-treat Asthma
Asthma in Children
Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52
Phase 4 N=25 Single Dose Bronchodilatory Study in Asthma
Asthma
Primary: Change From Baseline in FEV1 — 2.84 Liter
Phase 4 N=36 Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
Allergic Asthma
Primary: Change From Baseline in Total Subepithelial Eosinophils at the End of Week 78 (End of Treatment) — -5.807; -5.890; 1.555; -5.626 cells/mm^2
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
Phase 3 N=421 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change
Phase 3 N=342 Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)
Asthma
Primary: Time to Treatment Failure (Measured in Days) — 196.9; 225.2; 182.3 days
Phase 2 N=15 A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Severe, Refractory Asthma · Airway Inflammation · Airflow Obstruction
Primary: 16 Weeks - Juniper Asthma Quality of Life Questionnaire (AQLQ) Score — 4.7; 4.6 units on a scale
Early Phase 1 N=39 Defining and Treating Depression-related Asthma
Asthma · Depression · Childhood Asthma
Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032
Phase 3 N=376 Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Asthma
Primary: Change From Baseline to the Average of the Entire Treatment Period Reported, in the Average Pre-dose Morning Peak Expiratory Flow (PEF) — 16.45; -3.63 L/min — p=<0.001
N/A N=292 Asthma in Central Texas Project
Asthma
Primary: Absenteeism, End of Study — 3.83; 4.41; 3.68 percentage of days enrolled
N/A N=39 Inflammation and Corticosteroid Responsiveness in Severe Asthma
Asthma
Primary: Lung Function FEV1 — 84.9; 59.9 % of predicted — p=0.001
Phase 4 N=32 Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
Asthma
Primary: Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID. — 0.37; 0.21 mm/wk
Phase 2 N=606 Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate (AER) for Eosinophilic Phenotype (EOS+) Participants — 0.57; 0.65; 0.37; 0.34 AER events/person-year — p=0.781
Phase 3 N=285 Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
Asthma
Primary: Number of Patients With Drug-related Adverse Events — 3; 6; 10 participants
N/A N=530 School-based Asthma Therapy: Stage 2 Effectiveness Study
Asthma
Primary: Number of Symptom Free Days — 10.7; 11.6 Days
Phase 3 N=135 Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
Asthma
Primary: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control — 7…
Phase 4 N=406 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Asthma
Primary: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE) — 190; 29; 187; 28 participants
N/A N=351 Allergens in Inner-City Schools and Childhood Asthma
Asthma
Primary: Maximum Symptom Days/14 Days — 2.7 days